Obstetrics and Gynecology, Division of Gynecologic Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
Obstetrics and Gynecology, Division of Gynecologic Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Int J Gynecol Cancer. 2023 Nov 6;33(11):1778-1785. doi: 10.1136/ijgc-2023-004539.
Anemia is prevalent in patients with gynecologic cancers and is associated with increased peri-operative morbidity. We aimed to characterize risk factors for pre-operative anemia and describe outcomes among patients undergoing surgery by a gynecologic oncologist to identify potential areas for impactful intervention.
We analyzed major surgical cases performed by a gynecologic oncologist in the National Surgical Quality Improvement Program (NSQIP) database from 2014 to 2019. Anemia was defined as hematocrit <36%. Demographic characteristics and peri-operative variables for patients with and without anemia were compared using bivariable tests. Odds of peri-operative complications in patients stratified by pre-operative anemia were calculated using logistic regression models.
Among 60 017 patients undergoing surgery by a gynecologic oncologist, 23.1% had pre-operative anemia. Women with ovarian cancer had the highest rate of pre-operative anemia at 39.7%. Patients with advanced-stage cancer had a higher risk of anemia than early-stage disease (42.0% vs 16.3%, p≤0.001). In a logistic regression model adjusting for potential demographic, cancer-related, and surgical confounders, patients with pre-operative anemia had increased odds of infectious complications (odds ratio (OR) 1.16, 95% CI 1.07 to 1.26), thromboembolic complications (OR 1.39, 95% CI 1.15 to 1.68), and blood transfusion (OR 5.78, 95% CI 5.34 to 6.26).
There is a high rate of anemia in patients undergoing surgery by a gynecologic oncologist, particularly those with ovarian cancer and/or advanced malignancy. Pre-operative anemia is associated with increased odds of peri-operative complications. Interventions designed to screen for and treat anemia in this population have the potential for significant impact on surgical outcomes.
妇科癌症患者普遍存在贫血,且与围手术期发病率增加相关。本研究旨在明确术前贫血的危险因素,并描述由妇科肿瘤医生施行手术的患者的结局,以确定可能具有重要干预意义的领域。
我们分析了 2014 年至 2019 年国家外科质量改进计划(NSQIP)数据库中由妇科肿瘤医生施行的主要手术病例。将术前血细胞比容<36%定义为贫血。采用两变量检验比较贫血患者和非贫血患者的人口统计学特征和围手术期变量。采用 logistic 回归模型计算术前贫血分层患者围手术期并发症的发生概率。
在 60017 例行妇科肿瘤医生手术的患者中,23.1%存在术前贫血。卵巢癌患者术前贫血发生率最高,达 39.7%。与早期疾病相比,晚期癌症患者贫血风险更高(42.0% vs 16.3%,p≤0.001)。在调整潜在的人口统计学、癌症相关和手术混杂因素的 logistic 回归模型中,术前贫血患者发生感染性并发症(优势比(OR)1.16,95%置信区间(CI)1.07 至 1.26)、血栓栓塞性并发症(OR 1.39,95%CI 1.15 至 1.68)和输血(OR 5.78,95%CI 5.34 至 6.26)的概率更高。
由妇科肿瘤医生施行手术的患者贫血发生率较高,尤其是卵巢癌和/或晚期恶性肿瘤患者。术前贫血与围手术期并发症发生概率增加相关。针对该人群筛查和治疗贫血的干预措施可能对手术结局具有重要影响。